TuHURA Biosciences (NASDAQ:HURA) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

TuHURA Biosciences (NASDAQ:HURA) issued its quarterly earnings data on Friday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01, FiscalAI reports.

TuHURA Biosciences Price Performance

NASDAQ HURA traded up $0.17 during trading hours on Friday, reaching $2.47. The company’s stock had a trading volume of 317,089 shares, compared to its average volume of 1,079,055. The firm has a market capitalization of $157.30 million, a price-to-earnings ratio of -4.05 and a beta of -0.01. TuHURA Biosciences has a 1-year low of $0.41 and a 1-year high of $3.43. The company’s 50-day moving average is $2.27 and its two-hundred day moving average is $2.00.

Institutional Trading of TuHURA Biosciences

Several institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in shares of TuHURA Biosciences during the 3rd quarter worth approximately $26,000. JPMorgan Chase & Co. acquired a new stake in TuHURA Biosciences in the 2nd quarter valued at $27,000. Wells Fargo & Company MN increased its holdings in TuHURA Biosciences by 109.0% in the 4th quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock worth $29,000 after acquiring an additional 19,931 shares in the last quarter. Goldman Sachs Group Inc. purchased a new stake in TuHURA Biosciences in the 4th quarter worth $30,000. Finally, Invesco Ltd. acquired a new position in TuHURA Biosciences during the second quarter worth $30,000. 0.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on HURA shares. Citizens Jmp started coverage on TuHURA Biosciences in a research report on Monday, April 27th. They set a “market outperform” rating and a $9.00 price target for the company. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Friday, July 17th. Citigroup assumed coverage on shares of TuHURA Biosciences in a research note on Monday, April 27th. They set an “outperform” rating on the stock. Finally, Wall Street Zen lowered shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Sunday, May 31st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $9.00.

About TuHURA Biosciences

TuHURA Biosciences is a clinical?stage biotechnology company focused on the discovery and development of novel therapeutics using high?dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first?in?class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.